BOSTON ( TheStreet) -- Here's an updated list of biotech and pharmaceutical companies with pending FDA drug approval decisions for the rest of 2012 and into early 2013.
The calendar on the following pages captures the most important U.S. regulatory events -- FDA drug approvals and advisory panels -- expected between July and February 2013. As every savvy biotech investor and trader knows, the volatility in biotech and drug stocks ramps significantly as U.S. regulators weigh whether to approve or reject new drugs.
Biotech and drug stocks below are listed in chronological order based on the closest regulatory catalyst.
Drug/indication: Vascepa for triglyceride reduction
Approval decision date: July 26
Drug/indication: Lodotra for rheumatoid arthritis pain
Approval decision date: July 26 Salix Pharmaceuticals (SLXP) and Progenics (PGNX)
Drug/indication: Relistor SC for opioid-induced constipation
Approval decision date: July 27
This is an additional indication for currently approved Relistor. Regeneron Pharmaceuticals (REGN)
Drug/indication: Arcalyst for prevention of gout flares
Approval decision date: July 30
This will be the second approved indication for Arcalyst, which is currently marketed as a treatment for cryopyrin-associated periodic syndromes (CAPS). Regeneron Pharmaceuticals (REGN) and Sanofi (SNY)
Drug/indication: Zaltrap for colon cancer
Approval decision date: Aug. 4
Zaltrap has posted mixed results in phase III clinical trials. Talon Therapeutics (TLON)
Drug/indication: Marqibo for advanced acute lymphoblastic leukemia
Approval decision date: Aug. 12
In March, an FDA advisory panel voted to recommend approval of Marqibo. Gilead Sciences (GILD)
Drug/indication: Quad for HIV
Approval decision date: Aug. 27
Quad combines four Gilead drugs into a single, once-daily pill for HIV. The new (and still experimental) components in the Quad are the integrase inhibitor elvitegravir and cobicistat, which is used to boost blood levels of elvitegravir. Pfizer (PFE)
Drug/indication: Tofacitinib for rheumatoid arthritis
Approval decision date: August (exact date not specified)
Tofacitinib would be the first pill approved for the treatment of rheumatoid arthritis, competing with established injectable drugs like Abbbot's Humira. Ironwood Pharmaceuticals (IRWD)
Drug/indication: Linaclotide for chronic idiopathic constipation and irritable bowel syndrome
Approval decision date: Sept. 8 Navidea Biopharmaceuticals (NAVB)
Drug/indication: Lymphoseek, a radioactive tracing agent for lymph node mapping
Approval decision date: Sept. 10 Regeneron Pharmaceuticals (REGN)
Drug/indication: Eylea for Retinal Vein Occlusion (RVO)
Approval decision date: Sept. 21
This is an additional indication for currently approved Eylea. NPS Pharmaceuticals (NPSP)
Drug/indication: Gattex for short bowel syndrome
Approval decision date: Sept. 28
Drug/indication: Aubagio for multiple sclerosis
Approval decision date: Third quarter
Drug/indication: Abraxane for non-small cell lung cancer
Approval decision date: Oct. 12
Abraxane is already approved for the treatment of breast cancer.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV